EL7.AI
StocksMedium•18 November 2026•
4 min read

BillionToOne Responds to Short-Seller Report as Quarterly Revenue Grows 47%

Key Facts

1BillionToOne said it responded on November 18, 2026, to a Fuzzy Panda report published the same day.
2The company reported third-quarter 2026 revenue of $123 million, up 47% year over year.
3The company raised its 2026 revenue guidance to a range of $460–470 million.
4The company said it was reviewing the report with its legal advisers to consider available options.

BillionToOne said in a statement issued on November 18, 2026, that it was responding to a report published by Fuzzy Panda Research the same day, and described its claims as inaccurate, distorted, unsupported and misleading. The statement said Fuzzy Panda disclosed that it held a short position in the company’s securities and could benefit from a decline in its share price. The company did not accuse the firm of intending to manipulate the stock, but presented its disclosure of the position as a potential financial interest in a price decline. It said the report relied heavily on anonymous sources, selective data and speculative conclusions. It added that it stood behind the integrity of its practices, the quality of its tests, their clinical validity and the accuracy of its public disclosures. The company thus framed its response as rejecting the report’s allegations and defending its practices, while keeping those allegations attributed to the firm that published them.

Summaries of the report addressed allegations concerning the company’s test billing and the U.S. Medicaid program. Investing.com attributed to Fuzzy Panda the claim that Tennessee’s Medicaid Program Integrity office opened an inquiry in 2024 after receiving 11 reports, then referred the matter to the state bureau’s Medicaid Fraud Control Division. This is an account reported by the short seller, not an established official finding. The site also attributed to the report the claim that using unlisted billing codes generated about 10 times the usual rates. The same summary noted that the referral does not establish that a violation occurred or that formal charges were filed. The company’s statement did not confirm these allegations; instead, it said its billing practices, patient financial assistance and business dealings complied with applicable laws and regulations.

Separately, Investing.com attributed to Fuzzy Panda the claim that carrier screening tests appeared alongside about 88% of the non-invasive prenatal tests BillionToOne provided in Michigan Medicaid data from 2021 to 2026. The site said the report estimated that restricting claims it considered excessive for carrier screening could reduce earnings before interest, taxes, depreciation and amortization by about 80%. The report also modeled hypothetical penalties exceeding $1.2 billion under the False Claims Act. These are figures and estimates attributed to the short seller’s analysis, not established liabilities for the company. BillionToOne rejected what it called misleading allegations and said its business practices and healthcare compliance program were subject to applicable laws and regulations. Its statement provided no numerical details about these allegations or independent estimates of them.

The company said it was reviewing the report with its legal advisers to consider all available legal options, without announcing any specific legal action in its statement. Chief Executive and co-founder Özgürhan Atay said the company would continue to focus on patients, caregivers and shareholders. The remarks followed the announcement of third-quarter results on November 4, when revenue was $123 million, compared with $83.5 million in the corresponding quarter of 2025, an increase of 47% year over year. Revenue from oncology tests rose to $17.1 million in the third quarter of 2026, up 96% from $8.7 million a year earlier. Gross margin was 71%, compared with 70% in the corresponding quarter of 2025. These metrics were reported in the company’s quarterly results, not as a response to Fuzzy Panda’s allegations.

BillionToOne raised its fiscal 2026 revenue guidance to a range of $460 million to $470 million, equivalent to growth of between 51% and 54% compared with 2025. Its previous guidance range was $450 million to $465 million. On analyst coverage, Reuters reported that 7 of 8 brokerages recommended Buy or better, versus one Hold recommendation, while the average price target was $129, according to LSEG data as of November 18, 2026. These figures reflect analyst estimates and company guidance issued before the report; they do not resolve the validity of the allegations or the company’s response. Looking ahead, BillionToOne scheduled its participation in the Piper Sandler Annual Healthcare Conference for December 1, 2026. The company also said in its results that Northstar Clear, a test designed to detect residual tumor DNA without a tissue sample, would become commercially available on December 15, 2026.

Open on chart